Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Axcan, TPG Capital deal

TPG Capital will acquire AXCA for $23.35 per share, or about $1.3 billion in cash.

Read the full 151 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE